| Name | Title | Contact Details |
|---|
Egg Donation & Gestational Surrogacy services. Since 1996 ConceiveAbilities has professionally partnered with countless physicians and intended parents around the globe to help build families via third party reproduction. More than 20 years navigating the infertility industry has positioned ConceiveAbilities as the best partner to provide an unmatched level of service. Our unique and extensive experience and a reputation built on unparalleled service, knowledge and communication, allows us to cultivate excellent professional relationships with doctors and clinics, in addition to providing our clients, egg donors and surrogates with consistently solid service. Here at ConceiveAbilities, we believe that individuals and couples who have the desire to pursue a family, deserve the best support and resources possible. If you are committed to excellence and would like to join our team of enthusiastic dream-makers, we invite you to browse our webpage highlighting open positions among ConceiveAbilities` multiple locations.
BARRX, Inc is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. BARRX, Inc is based in Sunnyvale, CA. You can find more information on BARRX, Inc at www.barrx.com
Central Health Medicare Plan is a Covina, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Ample Scientific is a Norcross, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.